Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma

21 Mar 2014

Abstract excerpt

Natural killer (NK) cells are involved in immune surveillance of various malignancies, including multiple myeloma (MM).[1][1] IPH2101 is a fully human monoclonal antibody that blocks HLA-C binding KIR2D receptors (KIR2DL/DS-1, -2 -3) expressed on the surface of NK-cells, enhancing their cytotoxicity

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immune Cell Function and Interaction
Share to Multiple Myeloma Research and Treatments
Share to T-cell and B-cell Immunology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24658821
DOI: 10.3324/haematol.2013.103085

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myelomaPMID 24658821Read ↗

Killer cell immunoglobulin-like receptors in Thai patients with multiple myeloma.Semantic proximity Read ↗

HLA class I NK-epitopes and KIR diversities in patients with multiple myeloma.Semantic proximity Read ↗

Perspectives on Drug Development in Multiple Myeloma-Looking Forward to 2025.Semantic proximity Read ↗

Idelalisib — A PI3Kδ Inhibitor for B-Cell CancersSemantic proximity Read ↗

A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple MyelomaSemantic proximity Read ↗

Engineering NKG2D ligand affinity transforms EGFR-targeted NK cell engagers into high-potency effectors against pancreatic cancerSemantic proximity Read ↗

A Novel Hypothesis: Certain KIR/Cognate Ligand Containing Genotypes Differ in Frequency Among Patients With Myeloma and Have an Effect on Age of Disease Onset.Semantic proximity Read ↗

FcεRIγ-negative NK cells persist in vivo and enhance efficacy of therapeutic monoclonal antibodies in multiple myelomaSemantic proximity Read ↗

The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myelomaSemantic proximity Read ↗

Epitope characterization of a monoclonal antibody that selectively recognizes KIR2DL1 allotypes.Semantic proximity Read ↗

Targeting Bcl-2 for the treatment of multiple myeloma.Semantic proximity Read ↗

Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple MyelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.